Annexon To Highlight Phase 3 ARCHER II Clinical Trial Program At Virtual Investor Event
Benzinga Newsdesk 4 days ago
BiotechGeneralEventsNews
Company management will highlight the Phase 3 ARCHER II clinical trial design, patient demographics and communication strategy for the anticipated 15-month and 24-month results beginning in Q4 2026. The Company will
Company management will highlight the Phase 3 ARCHER II clinical trial design, patient demographics and communication strategy for the anticipated 15-month and 24-month results beginning in Q4 2026. The Company will also highlight the recent strengthening of its Ophthalmology team.